In a recent issue of Bone Marrow Transplantation, Dr Sairafi et al. 1 reported the results of a retrospective study to investigate the impact of NOD2/CARD15 single nucleotide polymorphisms (SNPs) on the outcome of allogeneic haematopoietic stem cell transplants (HSCT). They found no significant correlation between the presence of a NOD2/ CARD15 SNP and the incidence of acute GVHD, TRM, relapse-free survival or overall survival. We have recently reported the results of a retrospective analysis of the impact of NOD2/CARD15 SNPs on the outcome of 196 unrelated donor HSCT (UD-HSCT) pairs where the recipient was diagnosed with acute leukaemia. We found that the presence of a NOD2/CARD15 SNP correlated with a significant reduction in overall survival because of an increase in disease relapse. 2 Numerous other studies have shown the presence of SNPs to have a detrimental effect on the outcome of HSCT although the actual complication observed varies between groups and is thought to be dependent on specific characteristics of the cohort itself. [3] [4] [5] [6] [7] The authors discussed the possibility that differences in patient characteristics and transplant regimens between their cohort and those previously reported may explain why they failed to see significant effects on outcome where others have. Thus, we looked for any differences between the cohort described by Sairafi et al. and the patients in our study that might explain the divergent results. The most obvious difference is that their study comprised a mixture of related and UD sources, whereas our study focused solely on UD transplants. We found that the effect of NOD2/CARD15 SNPs was seen only in recipients with acute leukaemia and more specifically the effect was more pronounced in the ALL subgroup (Figure 1 ). This marked effect in acute leukaemia has also been reported in a related donor cohort, although, as previously, the outcome affected was different in the two studies based on differences in the clinical protocols used. 7 As 37% of the cohort studied by Sairafi et al. were recipients whose diagnosis was not acute leukaemia, the lack of effect seen in these recipients may mask any effect of the NOD2/ CARD15 SNPs in this study. The use and method of T-cell depletion was noticeably different when compared with our data, which we and others believe contributes significantly to the effect of any polymorphisms. 7, 8 In addition, the majority of transplants in the Sairafi study occurred when the recipient was considered to be in a lowrisk stage of their disease, which in itself may predict for a reduced risk of disease relapse. Finally, the frequency of NOD2/CARD15 SNPs seen in their study were markedly lower than in our cohort and in other HSCT studies. (The reported overall SNP frequency was 18% as compared with 27-29% in other studies.) 2, 4, 6 There is evidence to suggest that there is geographic variation in the prevalence of NOD2/CARD15 SNPs, which may explain the low frequency seen. 9 Thus, the lack of correlation to transplant outcome may be due to a lower prevalence of SNPs in this cohort.
It would be of interest to see if Sairafi et al. were able to see an effect in more homogeneous subgroups of their cohort, particularly in the acute leukaemia recipients and the UD pairs. This study adds much to the discussion that 
P=0.4042
SNP (n=25) SNP (n=23) WT (n=70) WT (n=53) P=0.0009 Figure 1 The impact of NOD2/CARD15 single nucleotide polymorphisms (SNPs) on disease relapse appears to be disease-specific. There is no significant impact of NOD2/CARD15 genotype on disease relapse for recipients diagnosed with CML (a) but a highly significant difference for those diagnosed with ALL (b).
the effects of NOD2/CARD15 polymorphisms on the outcome of HSCT are very much dependent on the combination of transplant regimen and donor source, and that interpretation and comparison of data must be thorough. In addition, it also shows that the variation of SNP frequencies in different populations can affect such studies. 
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